Mouse monoclonal antibodies were obtained by immunization with cultured human bladder cancer or lysates of bladder papilloma. They identify 11 distinct antigenic systems as defined by serological analysis of cultured cells and studies of antigen distribution in normal and neoplastic tissues. The most restricted of these antigens, OmS, defines a subset of bladder tumors. Om5 is not detected in normal bladder urothelium or in any other normal or malignant tissue. T101 and JP165 are also subset markers for bladder cancer that are not detected in normal tissues. T16, T43, T87, and J143 (antigens represented on many cultured cells) are found in specific areas of the normal urinary tract and in a distinctive range of other normal and malignant cell types-e.g., T16 expression in pluristratifiled epithelium of skin, exocervix, and esophagus. T138 antigen is also a common feature of cultured cell lines, but its expression in sections of normal tissues is restricted to endothelial cells. In contrast, T110 is poorly represented on cultured cells but can be detected in culture supernatants. Localization of T10 in normal tissues showed that it is a component of the extracellular matrix. All determinants detected by this series of antibodies are heat labile and not relat-
In our previous work, cultured cell lines were used to generate and analyze monoclonal antibodies (Abs) to cell surface antigens of melanoma (1), renal cancer (2) , and astrocytoma (3) . In the present study, the analysis is extended to bladder cancer. Antibody specificity has been defined by reactions with cultured cells and by reactions with normal adult and fetal tissues and with malignant tissues.
MATERIALS AND METHODS
Tissue Culture. Cultured lines of human bladder cancer came from the collection of J. Fogh (Sloan-Kettering Institute). The derivation and maintenance of other established human cell lines and the short-term culture of normal skin fibroblasts and kidney epithelial cells have been described (4, 5) .
Serological Procedures. Rosetting assays for the detection of cell surface antigens using rabbit anti-mouse Ig or goat anti-, chains conjugated to human 0 erythrocytes were performed as described (1) . Absorption tests, assessment of heat stability of the antigenic determinants, and Ouchterlony analysis of Ig subclasses were also performed as described (3, 4) . Enzyme-linked immunosorbent assays (ELISAs) were carried out with adherent monolayer cells or with proteins in the solid phase (6) . For hemagglutination assays, see ref. 7. Immunization. (BALB/c x C57BL/6) F1 female mice were immunized three or four times at intervals of 3-4 wk by intraperitoneal (i.p.) inoculation of 1 x 107 cells of T-24, 253-J, or 486-P and 253-J bladder cancer lines. For the derivation of Om Abs, a cell suspension was prepared from a bladder papilloma by mechanical dispersion and then extracted with 0.5% Nonidet P-40. One hundred micrograms of the papilloma extract was injected i.p. and 100 gg (in Freund's complete adjuvant) was injected subcutaneously. After 4 wk, an additional 100 jig of this extract was injected i.p.
Derivation of Mouse Monoclonal Antibodies. Mice were sacrificed 3-4 days after the final immunization and spleen cells were fused with mouse myeloma MOPC-21 NS/1 cells as described (1, 8 (9) . After subcloning three or four times, hybridomas were injected subcutaneously into nu/nu mice (Swiss background) and sera from mice growing tumors were used for serological and biochemical analysis of cultured cells.
Immunofluorescence Assays. Frozen sections (5 gm) of tissues were fixed for 5 min with 3.7% formaldehyde in phosphate-buffered saline, washed, and incubated for 1 hr with undiluted hybridoma culture supernatants. The slides were washed and incubated for 30 min with a 1:40 dilution of fluorescein-conjugated goat anti-mouse Ig (Cappel Laboratories, Cochranville, PA), washed again, and wet mounted in 90% glycerol in phosphate-buffered saline.
Immunoprecipitation Procedures. Antibodies were tested for immunoprecipitation activity by using detergent-solubilized cell extracts labeled by one of three methods: incorporation of [3H]lucosamine or [35S]methionine or surface labeling with 12 I (1, 3). Nonidet P-40 solubilization of cells and immunoprecipitation procedures using Staphylococcus aureus have been described (1, 3) . Molecular weights were determined under reducing conditions.
RESULTS
The mouse monoclonal antibodies generated in this series were generated by immunization with 253-J bladder cancer cells alone (AbJ143 and AbJ233) or in combination with 486-P cells (AbJP165) or by immunization with T24 cells (Abs  T16, T23, T43, T87, T101, T110, and T138 ). AbOm5 and AbOm37 were generated by immunization and initial screening with noncultured bladder papilloma. Antibody specificity was determined by direct or absorption tests (or both) on a panel of 75 tPositive on the basal cell layer only.
( Table 3) . Antigens detected by these antibodies were also characterized by immunoprecipitation tests (Fig. 1) strong expressors of J143 whereas noncultured specimens of these cancers were J14Y. T43 Antigenic System. AbT43 immunoprecipitated a glycoprotein of Mr 85,000. T43 was widely distributed on most cultured cell types with the exception of fibroblasts. In normal tissues, it was found only in proximal tubules of the kidney and the basal cell layer of the skin, exocervix, and esophagus. Normal urothelium of adult or fetus was T43-. A subset of bladder and renal tumors were T43 . In contrast to the T43+ phenotype of breast, lung, and colon cancers, benign tumors of these organs were T43-.
T23 Antigenic System. This antigen was expressed by a limited number of cultured cell types. In normal tissues, T23 was not detected on urothelium or other epithelial cells, but it was found on astrocytes; melanocytes; fibroblasts; smooth muscle; cartilage; and mature T lymphocytes of peripheral blood, spleen, lymph nodes, and thymic medulla. AbT23 identified a subset of bladder and kidney cancers In our past studies, we have distinguished antigens on the basis of wide, intermediate, or restricted distribution on the cultured cell panel. Of the 11 antigenic systems of bladder cancer defined in this study, 4 represent widely distributed antigens (T87, J143, T43, and T138), 4 are antigens of intermediate distribution (T16, T23, T101, and T110), and 3 show restricted distribution (Om5, J233, and JP165) with preferential expression on cell lines derived from renal and bladder cancers. Extending the analysis of these antibodies to reactions with normal and neoplastic tissues allows us to compare antigen expression in cultured vs. noncultured cells and to study cell types not represented in the cell panel. Some antigens show a relatively direct correlation between expression in vitro and in vivo. T87, J143, and T43, for example, are broadly represented on cultured cells and this parallels their expression on a range of normal and malignant cell types. Another example is JP165, which shows a restricted distribution on cultured bladder and renal cancers, and this pattern is similar to the expression of JP165 in tumor specimens, where expression is limited to a subset of renal and bladder cancers. The T16 phenotype of bladder, renal, and breast cancers also shows good concordance between cultured cell lines and tumor specimens; bladder and breast cancers are T16+ and renal cancers are T16-. There are, however, a number of discrepancies between antigen expression in cultured cells and in tissue sections. T101 and T138 are expressed by many cell types in vitro. In normal fetal and adult tissues, no T101 can be detected and T138 expression is restricted to endothelial cells. In tumor specimens, with the exception of bladder cancers, T101 and T138 expression is also more restricted than would have been predicted from results with cultured cells. (An opposite pattern-e.g., restricted distribution in vitro and broad distribution in vivo-has not been observed.) In addition, a number of instances have been found, particularly evident in the case of renal cancer (see e.g., J143 and T138) in which cultured cancer cells expressed antigen whereas specimens of the corresponding tumor type did not. An explanation for this may be that antigen expression is proliferation related and higher levels of these antigens would be expected on rapidly proliferating cultured cells.
A number of the antigens defined in this study were found in bladder cancers in vitro and in vivo but were not detected on normal bladder urothelium. In most of these instances of apparent "tumor specificity" with regard to the normal tissue counterpart, the antigens have been found in other normal tissues. However, two antigens detected on bladder cancer cells, OmS and J233, have not been found to be expressed by any cultured cells of normal origin or by normal adult or fetal tissues. Provocative as these findings are, particularly in the case of the Om antigen, claims for tumor specificity would be premature.
A frequent finding with monoclonal antibodies detecting cell surface antigens is the heterogeneity observed among cell lines derived from histologically similar tumor types. In the case of hematopoietic tumors (11) and melanoma (12) , the diversity in surface phenotype of tumors appears to reflect a corresponding diversity in the surface antigens of normal cells as they undergo progression through early, intermediate, and late stages of differentiation. Tumor subsets can be defined on the basis of these surface markers, and relating these surface markers to the biological behavior of tumors is an active area of interest. With the monoclonal antibodies generated in this study, bladder cancer lines and bladder cancer specimens can also be placed into distinct subsets. Current indications are that OmS identifies bladder tumors of low-grade malignancy, whereas T23, T43, and T138 characterize more aggressive tumors.
